Genitourinary Cancer News

Having type 2 diabetes before kidney removal surgery due to renal cell carcinoma can negatively affect survival and cancer recurrence outcomes, according to findings published in the Journal of Diabetes.

CHICAGO — Andrew Krivoshik, MD, PhD, senior vice president and oncology therapeutic area head at Astellas Pharma, spoke with HemOnc Today at ASCO Annual Meeting about key data presented this year.

UGN-101 gel induced complete response in a majority of patients with endoscopically unresectable low-grade upper tract urothelial cancer, according to results of the phase 3 OLYMPUS trial presented at American Urological Association Annual Meeting.

Click here to read the Cover Story, “Despite promising new regimens, search for cure is ‘highest priority’ in advanced renal cell carcinoma.”

With approximately 73,820 diagnoses and 14,770 deaths expected this year in the U.S., renal cell carcinoma remains a cancer in need of new treatment options.

About one in three cancer survivors, representing nearly 5.4 million people in the United States, reported experiencing chronic pain, with one in six survivors enduring high-impact chronic pain that limits life or work activities, according to a research letter published in JAMA Oncology. “Chronic pain is one of the most common long-term effects of cancer treatment and has been linked with an impaired quality of life, lower adherence to treatment, and higher health care costs,” Changchuan Jiang, MD, MPH, resident in internal medicine at Mount Sinai Hospital, and colleagues wrote. “Nevertheless, there is a paucity of information regarding the prevalence of, and risk factors for, the development of chronic pain among cancer survivors.”

The FDA granted fast track designation to TRQ-1501, a deep-primed IL-15 T-cell immunotherapy for the treatment of relapsed or refractory solid tumors and lymphomas that express any of five tumor-associated antigens, according to the agent’s manufacturer.

CHICAGO — The investigational therapy enfortumab vedotin demonstrated an objective response rate of 44% among a cohort of patients with locally advanced or metastatic urothelial cancer whose disease progressed after two previous lines of therapy, according to results from the single-arm, phase 2 EV-201 study presented at ASCO Annual Meeting.

Bladder cancer is one of the most common forms of cancer in United States, with an estimated 81,190 new cases and 17,240 deaths in 2018.

CHICAGO — States that expanded Medicaid under the Affordable Care Act appeared to eliminate disparities in timely treatment for black patients with cancer compared with white patients, according to results of a retrospective observational study presented during the plenary session at ASCO Annual Meeting.